Xeno Biosciences Inc., a company focused on advancing therapies for obesity and metabolic diseases, has initiated a Phase 1b clinical study to evaluate the efficacy, safety, and tolerability of its…
Takeda (TSE:4502/NYSE) unveiled encouraging findings from its Phase 2b study, which evaluated mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare bleeding disorder caused by…
OrsoBio, Inc., a clinical-stage biopharmaceutical company focused on treatments for obesity and associated disorders, has unveiled new data for its liver-targeted mitochondrial protonophore, TLC-6740, at the 84th Scientific Sessions of…
BioHorizons today announced the release of Tapered Pro Conical, its inaugural dental implant incorporating a deep conical connection. This new implant underscores BioHorizons’ commitment to developing innovative products that enhance…
NRC Health’s Human Understanding Beyond | HUB24 offers an opportunity to explore cutting-edge solutions, best practices, and forward-thinking strategies aimed at enhancing experiences for patients, consumers, and employees. In an…
At the European Hematology Association (EHA) 2024 Hybrid Congress, the data from InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented, showcasing significant advancements in various areas of hematology research…
AstraZeneca’s FARXIGA® (dapagliflozin) has received approval from the US Food and Drug Administration (FDA) for improving glycemic control in pediatric patients with type-2 diabetes (T2D) aged 10 years and older.…
The Frankfurt (Oder) Clinic warmly invites you to attend the next themed afternoon as part of the AOK Pfiffs training program. This free event, featuring nutritionist Anja Dehl and pharmacist…
AcariaHealth, a national specialty pharmacy dedicated to improving care and outcomes for patients with complex medical conditions and a wholly owned subsidiary of Centene Corporation (NYSE: CNC), has announced the…
Dr. Michael Schönhofen, head of Fresenius Kabi’s Biopharma business, will leave the company on June 30, 2024, after over 30 successful years. His successor, Dr. Sang-Jin Pak, will join the…
In the dynamic realm of healthcare, the quest for effective interventions persists. Whether it’s pioneering medications, advanced medical tools, or novel treatment approaches, the path from discovery to application is…
MultiPlan Corporation (NYSE: MPLN), a prominent provider of data analytics and technology-driven cost management solutions in the U.S. healthcare sector, has announced the release of its 2023 Environmental, Social, and…